
Artificial Intelligence can compress drug development from five to seven years to just one or two years, Biocon Executive Chairperson Kiran Mazumdar-Shaw said on Tuesday (17 November 2026) at the Bengaluru Tech Summit. She said AI will transform patient selection and early readouts in clinical trials, enabling next-generation drugs and diagnostics such as detecting the first cancer cell.

Shaw stressed that regulations must keep pace with faster discovery, noting discussions in Karnataka on creating a ‘regulatory sandbox’ to validate proof of concepts more swiftly. She described biology as the most important frontier for AI deployment, saying the technology will help scientists simplify complex biological systems. The three-day summit continues through 19 November 2026.
Both rediff.com and Business Standard carried the same PTI-sourced report on Kiran Mazumdar-Shaw's Tuesday speech at the Bengaluru Tech Summit 2026. The coverage is uniform straight reporting with no discernible editorial slant on the government. Rediff.com used an AI-generated headline and added a disclaimer about AI-selected content, which is a production choice rather than a framing shift. Business Standard appended an 'Also Read' widget. The only substantive divergence is that rediff.com’s headline is more direct: 'AI To Accelerate Drug Development Significantly'. The consensus story focuses on Shaw’s optimism about compressing drug timelines to one or two years, the need for regulatory sandboxes in Karnataka, and AI's role in precision medicine. The next named step is the three-day Bengaluru Tech Summit, which started on 17 November 2026.
Coverage: 2 sources, 2 neutral
Sources (2): rediff.com (neutral report), business-standard.com (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.